汪福群  王胜炳  刘波颖

[摘要] 目的 对乙肝后肝硬化失代偿期患者分别采用抗病毒治疗和一般护肝治疗，观察两组患者的临床疗效及经济学效益差异。 方法 选择我院接诊的155例乙肝后肝硬化失代偿期患者，其中98例患者采用抗病毒治疗（实验组），57例患者仅采用一般护肝治疗（对照组）。疗程结束后，观察两组患者的临床疗效，同时进行经济成本与效果分析。 结果 实验组患者死亡5例，对照组患者死亡18例，占总死亡率的78.2%。且临床疗效实验组患者明显优于对照（P＜0.05）；经济成本与效果分析，实验组患者经济成本明显低于对照组（P＜0.05）。 结论 采用抗病毒药物治疗乙肝后肝硬化失代偿期患者疗效好、费用低，是治疗乙肝后肝硬化失代偿期患者的重要治疗手段。

[关键词] 乙型肝炎；乙肝后肝硬化失代偿期；疗效；经济学研究

[中图分类号] R512.62   [文献标识码] B   [文章编号] 2095-0616（2014）08-174-03

Study of efficacy and economics of antiviral treatment of decompensated liver cirrhosis following hepatitis B

WANG Fuqun  WANG Shengbing  LIU Boying

Department of Gastroenterology, Meizhou People's Hospital, Meizhou 514031,China

[Abstract] Objective To observe the differences in clinical efficacy and economic benefits between the two groups of patients with decompensated liver cirrhosis following hepatitis B who received antiviral treatment and ordinary liver protection treatment respectively. Methods 155 patients with decompensated liver cirrhosis following hepatitis B who were admitted to our hospital were selected, of which 98 patients received antiviral treatment(experimental group) and 57 patients only received ordinary liver protection treatment(control group). After treatment, clinical efficacy of the two groups was observed and meanwhile their economic costs and effects were analyzed. Results Five patients died in the experimental group and 18 patients died in the control group, accounting for 78.2% of the total death rate. The experimental group had significantly better clinical efficacy than the control group(P＜0.05); In terms of economic cost and effect analysis, the experimental group had significantly lower economic cost than the control group(P＜0.05). Conclusion In the treatment of decompensated liver cirrhosis following hepatitis B, antiviral drug treatment has good efficacy and low cost, which is an important treatment method for the patients with decompensated liver cirrhosis following hepatitis B.

[Key words] Hepatitis B;Decompensated liver cirrhosis following hepatitis B;Efficacy;Economic study

乙肝后肝硬化失代偿期患者，体内HBV复制活跃，若此时不能给予有效的抗病毒药物，抑制肝炎病毒的复制，将会产生多种并发症，例如上消化道出血、腹水，进而发展为慢性肝衰竭而导致死亡；另外，有些患者会发生肝性脑病，致死、致残率极高。据统计，乙肝后肝硬化失代偿期患者的5年生存率仅为14%[1]，严重影响患者的生命安全。随着抗病毒药物的广泛应用，部分乙肝后肝硬化失代偿期患者的病情得到有效控制和改善。本文对乙肝后肝硬化失代偿期患者分别采用抗病毒治疗和一般护肝治疗，并分析其疗效和经济学成本，为临床提供用药指导。……